Cargando…
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon
Cancer vaccines based on mRNA are extensively studied. The fragile nature of mRNA has instigated research into carriers that can protect it from ribonucleases and as such enable its systemic use. However, carrier-mediated delivery of mRNA has been linked to production of type I interferon (IFN) that...
Autores principales: | Broos, Katrijn, Van der Jeught, Kevin, Puttemans, Janik, Goyvaerts, Cleo, Heirman, Carlo, Dewitte, Heleen, Verbeke, Rein, Lentacker, Ine, Thielemans, Kris, Breckpot, Karine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022130/ https://www.ncbi.nlm.nih.gov/pubmed/27327138 http://dx.doi.org/10.1038/mtna.2016.38 |
Ejemplares similares
-
mRNA in cancer immunotherapy: beyond a source of antigen
por: Van Hoecke, Lien, et al.
Publicado: (2021) -
Targeting the tumor microenvironment to enhance antitumor immune responses
por: Van der Jeught, Kevin, et al.
Publicado: (2014) -
Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8(+) T cell and iNKT cell activating mRNA vaccine
por: Ertveldt, Thomas, et al.
Publicado: (2023) -
Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines
por: Goyvaerts, Cleo, et al.
Publicado: (2015) -
The dawn of mRNA vaccines: The COVID-19 case
por: Verbeke, Rein, et al.
Publicado: (2021)